NK cells and cancer immunosurveillance

Natural killer (NK) cells are lymphocytes of the innate immune system that monitor cell surfaces of autologous cells for an aberrant expression of MHC class I molecules and cell stress markers. Since their first description more than 30 years ago, NK cells have been implicated in the immune defence against tumours. Here, we review the broadly accumulating evidence for a crucial contribution of NK cells to the immunosurveillance of tumours and the molecular mechanisms that allow NK cells to distinguish malignant from healthy cells. Particular emphasis is placed on the activating NK receptor NKG2D, which recognizes a variety of MHC class I-related molecules believed to act as ‘immuno-alerters’ on malignant cells, and on tumour-mediated counterstrategies promoting escape from NKG2D-mediated recognition.

[1]  Mark J. Smyth,et al.  Perforin-mediated target-cell death and immune homeostasis , 2006, Nature Reviews Immunology.

[2]  H. Ljunggren,et al.  In search of the 'missing self': MHC molecules and NK cell recognition. , 1990, Immunology today.

[3]  N. Hayashi,et al.  Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid , 2003, International journal of cancer.

[4]  R. Herberman,et al.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity , 1975, International journal of cancer.

[5]  L. Lanier,et al.  Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Miller,et al.  CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. , 1996, Blood.

[7]  S. Nutt,et al.  Functional subsets of mouse natural killer cells , 2006, Immunological reviews.

[8]  H. Inoko,et al.  MIC and other NKG2D ligands: from none to too many. , 2005, Current opinion in immunology.

[9]  P. Parham.  MHC class I molecules and kirs in human history, health and survival , 2005, Nature Reviews Immunology.

[10]  Michael J. Wilson,et al.  A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3. , 2002, Genomics.

[11]  E. Alnemri,et al.  Natural Killer (NK) Cell–mediated Cytotoxicity: Differential Use of  TRAIL and Fas Ligand by Immature and Mature Primary Human NK Cells , 1998, The Journal of experimental medicine.

[12]  C. Biron,et al.  Natural killer cells in antiviral defense: function and regulation by innate cytokines. , 1999, Annual review of immunology.

[13]  C. Kalberer,et al.  Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. , 2005, Blood.

[14]  M. Smyth,et al.  Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells , 2004, The Journal of experimental medicine.

[15]  A. Diefenbach,et al.  A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity , 2003, European journal of immunology.

[16]  É. Vivier,et al.  Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D , 2002, Nature Immunology.

[17]  C. Münz,et al.  NK Cell Compartments and Their Activation by Dendritic Cells1 , 2004, The Journal of Immunology.

[18]  L. Lanier,et al.  Cutting Edge: Lectin-Like Transcript-1 Is a Ligand for the Inhibitory Human NKR-P1A Receptor1 , 2005, The Journal of Immunology.

[19]  I. Herr,et al.  Natural killer resistance of a drug-resistant leukemia cell line, mediated by up-regulation of HLA class I expression. , 2003, Haematologica.

[20]  Dong-Wan Kim,et al.  Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients1 , 2004, The Journal of Immunology.

[21]  Jun Wu,et al.  An activating immunoreceptor complex formed by NKG2D and DAP10. , 1999, Science.

[22]  Ofer Levi,et al.  Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus , 2005, Nature Immunology.

[23]  R. Kiessling,et al.  „Natural”︁ killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell , 1975, European journal of immunology.

[24]  N. Shastri,et al.  Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages , 2000, Nature Immunology.

[25]  S. Coca,et al.  Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. , 2002, Lung cancer.

[26]  R. Biassoni,et al.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. , 2001, Annual review of immunology.

[27]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[28]  H. Rammensee,et al.  Systemic NKG2D Down-Regulation Impairs NK and CD8 T Cell Responses In Vivo1 , 2005, The Journal of Immunology.

[29]  L. Thomsen,et al.  Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. , 2004, Nature immunology.

[30]  T. Enver,et al.  CD56bright Human NK Cells Differentiate into CD56dim Cells: Role of Contact with Peripheral Fibroblasts , 2007, The Journal of Immunology.

[31]  J. Trowsdale,et al.  Comparative Genomics of Natural Killer Cell Receptor Gene Clusters , 2005, PLoS genetics.

[32]  C. Sutherland,et al.  UL16-Binding Proteins, Novel MHC Class I-Related Proteins, Bind to NKG2D and Activate Multiple Signaling Pathways in Primary NK Cells , 2002, The Journal of Immunology.

[33]  T. Mcclanahan,et al.  Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. , 2000, Immunity.

[34]  R. Kiessling.  NATURAL KILLER CELLS IN THE MOUSE , 1976 .

[35]  P. Kuppen,et al.  NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. , 2003, Trends in immunology.

[36]  O. Mandelboim,et al.  Tumor and viral recognition by natural killer cells receptors. , 2006, Seminars in cancer biology.

[37]  J. Becker,et al.  Expression of stress-induced MHC class I related chain molecules on human melanoma. , 2002, The Journal of investigative dermatology.

[38]  Michael Hallek,et al.  Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. , 2007, Immunity.

[39]  D. Fremont,et al.  Cutting Edge: Murine UL16-Binding Protein-Like Transcript 1: A Newly Described Transcript Encoding a High-Affinity Ligand for Murine NKG2D1 , 2002, The Journal of Immunology.

[40]  I. Weissman,et al.  In vivo natural killer cell activities revealed by natural killer cell-deficient mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Lewis L Lanier,et al.  NK cell recognition. , 2005, Annual review of immunology.

[42]  M. Martelli,et al.  Natural killer cell alloreactivity in allogeneic hematopoietic transplantation , 2007, Current opinion in oncology.

[43]  L. Lanier,et al.  A Structural Basis for the Association of DAP12 with Mouse, but Not Human, NKG2D1 , 2004, The Journal of Immunology.

[44]  M. Smyth,et al.  NKG2D function protects the host from tumor initiation , 2005, The Journal of experimental medicine.

[45]  R. Strong,et al.  Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands , 2007, Nature.

[46]  H. Pircher,et al.  Cutting Edge: Identification of E-Cadherin as a Ligand for the Murine Killer Cell Lectin-Like Receptor G11 , 2006, The Journal of Immunology.

[47]  Kazuyoshi Takeda,et al.  New aspects of natural-killer-cell surveillance and therapy of cancer , 2002, Nature Reviews Cancer.

[48]  R. Dummer,et al.  Human leukocyte antigen-G and cancer immunoediting. , 2008, Cancer research.

[49]  H. Rammensee,et al.  Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding , 2002, The Journal of Immunology.

[50]  N. Matsumoto,et al.  Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity , 2006, The Journal of experimental medicine.

[51]  Dong-Wan Kim,et al.  Elevated TGF-b1 Secretion and Downmodulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients , 2004 .

[52]  D. Pardoll.  Stress, NK Receptors, and Immune Surveillance , 2001, Science.

[53]  R. Armitage,et al.  ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. , 2001, Immunity.

[54]  D. Raulet.  Interplay of natural killer cells and their receptors with the adaptive immune response , 2004, Nature Immunology.

[55]  L. Lanier.  NK cell receptors. , 1998, Annual review of immunology.

[56]  Arthur I. Roberts,et al.  Cutting Edge: NKG2D Receptors Induced by IL-15 Costimulate CD28-Negative Effector CTL in the Tissue Microenvironment1 , 2001, The Journal of Immunology.

[57]  H. Salih,et al.  Soluble MICA in malignant diseases , 2006, International journal of cancer.

[58]  D. Geraghty,et al.  A second lineage of mammalian major histocompatibility complex class I genes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[59]  S. Welte,et al.  Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction , 2006, Nature Immunology.

[60]  B. Plougastel,et al.  Immune functions encoded by the natural killer gene complex , 2003, Nature Reviews Immunology.

[61]  W. Fanslow,et al.  ULBP1, 2, 3: novel MHC class I‐related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells , 2001, European journal of immunology.

[62]  P. Romero.  Faculty Opinions recommendation of NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. , 2002 .

[63]  J. Bell,et al.  HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C , 1998, Nature.

[64]  T. Spies,et al.  Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB , 1999 .

[65]  Eric Vivier,et al.  Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future , 2004, Nature Reviews Immunology.

[66]  F. Bach,et al.  DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells , 1991, The Journal of experimental medicine.

[67]  H. Ljunggren,et al.  Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism , 1985, The Journal of experimental medicine.

[68]  W. Yokoyama,et al.  How do natural killer cells find self to achieve tolerance? , 2006, Immunity.

[69]  G. Rabinovich,et al.  Activation‐induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28 , 2002, Journal of leukocyte biology.

[70]  H. Rammensee,et al.  Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. , 2003, Blood.

[71]  U. Koszinowski,et al.  Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses , 2003 .

[72]  D. Raulet.  Roles of the NKG2D immunoreceptor and its ligands , 2003, Nature Reviews Immunology.

[73]  P. Sun,et al.  Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. , 2001, Immunity.

[74]  T. Spies,et al.  Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[75]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[76]  S. Honda,et al.  Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. , 2006, Blood.

[77]  S. Nutt,et al.  Interleukin 21: a key player in lymphocyte maturation. , 2004, Critical reviews in immunology.

[78]  M. Colonna,et al.  NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation , 2002, Nature Immunology.

[79]  M. Korc,et al.  Membrane-Associated Heparan Sulfate Proteoglycans Are Involved in the Recognition of Cellular Targets by NKp30 and NKp461 , 2004, The Journal of Immunology.

[80]  A. Hayday,et al.  Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance , 2005, Nature Immunology.

[81]  Eric J. Brown,et al.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.

[82]  M. Smyth,et al.  Innate immune recognition and suppression of tumors. , 2006, Advances in cancer research.

[83]  P. Leibson,et al.  NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells , 2006, Nature Immunology.

[84]  D. Fremont,et al.  Ligands for murine NKG2D display heterogeneous binding behavior. , 2002, European journal of immunology.

[85]  D. Olive,et al.  Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. , 2002, Blood.

[86]  M. Llano,et al.  HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[87]  R. Kiessling,et al.  „Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype , 1975, European journal of immunology.

[88]  W. Seaman,et al.  The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex. , 1993, Annual review of immunology.

[89]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[90]  L. Moretta,et al.  Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.

[91]  M. Smyth,et al.  Immune surveillance of tumors. , 2007, The Journal of clinical investigation.

[92]  Lewis L Lanier,et al.  Natural killer cells and cancer. , 2003, Advances in cancer research.

[93]  D. Raulet,et al.  Expression and function of NK cell receptors in CD8+ T cells. , 2001, Current opinion in immunology.

[94]  L. Lanier.  A renaissance for the tumor immunosurveillance hypothesis , 2001, Nature Medicine.

[95]  W. Yokoyama,et al.  Natural killer cells and viral infections. , 2003, Current opinion in immunology.

[96]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[97]  S. Tangye,et al.  Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. , 2007, Annual review of immunology.

[98]  L. Notarangelo,et al.  X-Linked Lymphoproliferative Disease 2b4 Molecules Displaying Inhibitory Rather than Activating Function Are Responsible for the Inability of Natural Killer Cells to Kill Epstein-Barr Virus–Infected Cells , 2000 .

[99]  K. Wucherpfennig,et al.  The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[100]  L. Lanier,et al.  DAP12: an adapter protein with dual functionality , 2006, Immunological reviews.

[101]  R. Herberman,et al.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells , 1975, International journal of cancer.

[102]  D. Busch,et al.  DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. , 2005, Blood.

[103]  S. Riddell,et al.  Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. , 2001, Nature immunology.

[104]  C. Kuijl,et al.  MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. , 2001, Immunity.

[105]  R. Biassoni,et al.  Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin , 2001, European journal of immunology.

[106]  T. Spies,et al.  MICA Engagement by Human Vγ2Vδ2 T Cells Enhances Their Antigen-Dependent Effector Function , 2001 .

[107]  A. Hayday,et al.  Regulation of cutaneous malignancy by gammadelta T cells. , 2001, Science.

[108]  M. Horowitz,et al.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. , 2005, Blood.

[109]  A. Steinle,et al.  Proteolytic release of soluble UL16-binding protein 2 from tumor cells. , 2006, Cancer research.

[110]  L. Lanier,et al.  Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family , 2001, Immunogenetics.

[111]  A. Diefenbach,et al.  Strategies for target cell recognition by natural killer cells , 2001, Immunological reviews.

[112]  R. Biassoni,et al.  Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[113]  T. Goldmann,et al.  Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. , 2008, Lung cancer.

[114]  L. Moretta,et al.  Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. , 2006, Blood.

[115]  D. Fremont,et al.  Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors , 2003, Nature Immunology.

[116]  B. Plougastel,et al.  Costimulation of Multiple NK Cell Activation Receptors by NKG2D1 , 2002, The Journal of Immunology.

[117]  D. Olive,et al.  NK cells: innate immunity against hematological malignancies? , 2004, Trends in immunology.

[118]  S. Ferrone,et al.  HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? , 2005, Cancer research.

[119]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[120]  L. Moretta,et al.  PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. , 2005, Molecular immunology.

[121]  M. Weller,et al.  RNA Interference Targeting Transforming Growth Factor-β Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In vivo , 2004, Cancer Research.

[122]  L. Moretta,et al.  The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. , 2006, Blood.

[123]  Eric O Long,et al.  Killer cell inhibitory receptors: diversity, specificity, and function , 1997, Immunological reviews.

[124]  S. Bahram,et al.  Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[125]  A. Diefenbach,et al.  The role of the NKG2D immunoreceptor in immune cell activation and natural killing. , 2002, Immunity.

[126]  S. Gasser,et al.  Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[127]  R. Biassoni,et al.  Receptors for HLA class-I molecules in human natural killer cells. , 1996, Annual review of immunology.

[128]  G. Morgan,et al.  The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. , 2007, Cancer research.

[129]  G. McDermott,et al.  Crystal structures of RAE-1beta and its complex with the activating immunoreceptor NKG2D. , 2002, Immunity.

[130]  K. Haugk,et al.  Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. , 2004, The Journal of clinical investigation.

[131]  A Steinle,et al.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.

[132]  H. Ljunggren,et al.  DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. , 2007, Cancer research.

[133]  T. Spies,et al.  Fas ligand–mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity , 2006, Nature Immunology.

[134]  F. Bihl,et al.  Cutting Edge: Lectin-Like Transcript 1 Is a Ligand for the CD161 Receptor1 , 2005, The Journal of Immunology.

[135]  M. Smyth,et al.  CD27 Dissects Mature NK Cells into Two Subsets with Distinct Responsiveness and Migratory Capacity1 , 2006, The Journal of Immunology.

[136]  T. Sayers,et al.  NKG2D Recognition and Perforin Effector Function Mediate Effective Cytokine Immunotherapy of Cancer , 2004, The Journal of experimental medicine.

[137]  H. Salih,et al.  Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA , 2006, Cancer Immunology, Immunotherapy.

[138]  M. A. Sáez,et al.  The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma , 1997, Cancer.

[139]  J. Trowsdale,et al.  Promiscuity and the single receptor: NKG2D , 2007, Nature Reviews Immunology.

[140]  T. Joh,et al.  Genomic structures and characterization of Rae1 family members encoding GPI-anchored cell surface proteins and expressed predominantly in embryonic mouse brain. , 1996, Journal of biochemistry.

[141]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[142]  D. Middleton,et al.  Human NK cell education by inhibitory receptors for MHC class I. , 2006, Immunity.

[143]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[144]  J. Trowsdale,et al.  Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. , 2007, Blood.

[145]  S. Natsugoe,et al.  Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.

[146]  S. Bauer,et al.  Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[147]  Julia M. Lewis,et al.  Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.

[148]  É. Vivier,et al.  Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses. , 2007, Current opinion in immunology.

[149]  J. Coligan,et al.  IL-21 Down-Regulates NKG2D/DAP10 Expression on Human NK and CD8+ T Cells1 , 2006, The Journal of Immunology.

[150]  K. Nakachi,et al.  Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population , 2000, The Lancet.

[151]  F. Garrido,et al.  The HLA crossroad in tumor immunology. , 2000, Human immunology.

[152]  M. Caligiuri,et al.  Human natural killer cell development , 2006, Immunological reviews.

[153]  L. Lybarger,et al.  Licensing of natural killer cells by host major histocompatibility complex class I molecules , 2005, Nature.

[154]  P. Bjorkman,et al.  Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. , 2001, Immunity.

[155]  G F Babcock,et al.  Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. , 1983, Journal of immunology.

[156]  R. Schreiber,et al.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[157]  R. Kroczek,et al.  Coordinate Expression of Cytokines and Chemokines by NK Cells during Murine Cytomegalovirus Infection1 , 2004, The Journal of Immunology.

[158]  M. Weller,et al.  TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. , 2006, Brain : a journal of neurology.

[159]  M. Colonna,et al.  Patients with X‐linked lymphoproliferative disease have a defect in 2B4 receptor‐mediated NK cell cytotoxicity , 2000, European journal of immunology.

[160]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[161]  W. Yokoyama,et al.  MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells , 1992, Nature.

[162]  Angel Porgador,et al.  Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells , 2001, Nature.

[163]  R. Vance,et al.  Self-tolerance of natural killer cells , 2006, Nature Reviews Immunology.

[164]  R. Strong,et al.  Complex structure of the activating immunoreceptor NKG2D and its MHC class I–like ligand MICA , 2001, Nature Immunology.

[165]  L. Lanier,et al.  Cutting Edge: Toll-Like Receptor Signaling in Macrophages Induces Ligands for the NKG2D Receptor 1 , 2004, The Journal of Immunology.

[166]  Judy Lieberman,et al.  Cell death and immunity: The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal , 2003, Nature Reviews Immunology.

[167]  A. Neil Barclay,et al.  2B4, the Natural Killer and T Cell Immunoglobulin Superfamily Surface Protein, Is a Ligand for CD48 , 1998, The Journal of experimental medicine.

[168]  M. Weller,et al.  TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells , 2006 .